Neonatal Hyperbilirubinemia Management

Initial Assessment and Monitoring

• The American Academy of Pediatrics (AAP) recommends systematic jaundice assessment for all newborns at least every 8–12 hours during hospitalization, with nursing staff authorized to obtain transcutaneous bilirubin (TcB) or order total serum bilirubin (TSB) when jaundice is detected. 1
• Visual estimation of jaundice severity is unreliable—particularly in infants with darker skin pigmentation—and should never be used to guide treatment decisions. 2
• Jaundice typically spreads from the face to the trunk and extremities, but the extent of skin discoloration does not reliably correlate with serum bilirubin levels. 1

Laboratory Evaluation

• TSB (rather than TcB alone) must be obtained for any infant with visible jaundice in the first 24 hours of life or when jaundice appears excessive for the infant’s age. 1
• When the mother’s blood type is O Rh‑positive, cord or infant blood should be tested for ABO/Rh type and a direct antiglobulin test (DAT). 1
• Any infant who requires phototherapy should have the underlying cause of hyperbilirubinemia evaluated. 2
• If TSB rises despite intensive phototherapy, rises suddenly after an initial decline, persists beyond 3 weeks, or escalation of care is needed, a work‑up including CBC with peripheral smear, reticulocyte count, blood type, DAT, and G6PD activity is indicated. [2][1]
• For infants jaundiced beyond 3 weeks, total and direct (conjugated) bilirubin should be measured, and newborn thyroid and galactosemia screening results verified. 1

Interpretation of Bilirubin Levels and Risk Stratification

• All bilirubin values must be plotted on hour‑specific nomograms that incorporate exact age in hours, gestational age, and neurotoxicity risk factors. [2][1]
• Lower phototherapy treatment thresholds apply to infants with gestational age 35–37 weeks, isoimmune hemolytic disease (positive DAT), and G6PD deficiency. [2][1]

Phototherapy Indications and Technique

• The 2024 AAP hour‑specific phototherapy nomograms, which factor in gestational age, neurotoxicity risk factors, and infant age in hours, should be used to determine when to start phototherapy. 2
• Intensive phototherapy should maximize skin exposure and employ blue‑green spectrum light (blue fluorescent tubes or LED devices) delivering spectral irradiance > 30 μW/cm²/nm. 3

Monitoring During Phototherapy

• TSB must be measured after initiating phototherapy to verify efficacy; the timing of repeat testing should be based on the rate of bilirubin rise (mg/dL per hour) and the infant’s age. 2
• TcB measurements are unreliable during phototherapy and for up to 24 hours after cessation because light “bleaches” the skin; TSB should be used instead. 2

Discontinuation of Phototherapy

• Phototherapy should be stopped when TSB has fallen 2–4 mg/dL below the hour‑specific threshold at which phototherapy was started. 2
• Decisions to discontinue should also consider the underlying cause of hyperbilirubinemia, the gap between current TSB and the phototherapy threshold, and the risk of rebound hyperbilirubinemia. 2

Post‑Phototherapy Follow‑Up

• High‑risk infants (phototherapy initiated < 48 hours of age, gestational age < 38 weeks, positive DAT, or suspected hemolytic disease) require a TSB measurement 8–12 hours after phototherapy cessation and a repeat measurement the following day. 2
• All other infants should have a TSB checked within 1–2 days after stopping phototherapy. 2

Escalation of Care and Exchange Transfusion

• Immediate escalation of care is mandated when TSB reaches or exceeds the exchange‑transfusion threshold, or lies within 0–2 mg/dL below that threshold. 2
• At the escalation threshold, intravenous hydration and emergent intensive phototherapy must be started promptly. 2
• During escalation, TSB should be measured at least every 2 hours until the escalation period ends. 2
• If TSB continues to rise despite intensive phototherapy and IV hydration, neonatology consultation for NICU transfer is required. 2
• The bilirubin‑to‑albumin (B/A) ratio may be used as an adjunctive factor—though never in place of TSB—when deciding on exchange transfusion. 3

Home Phototherapy Option

• For infants who have been discharged and subsequently develop a TSB above the phototherapy threshold, home‑based LED phototherapy is an option provided the infant is clinically stable, feeding adequately, the family is reliable, and close outpatient follow‑up can be arranged. 2

Discharge Planning and Follow‑Up

• Prior to discharge, appropriate surveillance, risk assessment, and follow‑up arrangements must be ensured for every infant. 1

Management of Jaundice in Neonates

Initial Assessment and Laboratory Evaluation

• The American Academy of Pediatrics recommends obtaining both total serum bilirubin (TSB) and direct/conjugated bilirubin levels in any infant with jaundice at 10 days of age, as this falls within the timeframe requiring evaluation for pathologic causes 4, 5, 6
• Transcutaneous bilirubin (TcB) measurements can be used for screening if TSB is expected to be <15 mg/dL, but TSB is more definitive at this age 5, 7
• All bilirubin levels must be interpreted according to the infant's age in hours (240 hours at 10 days), not just days of life 4, 5, 8

Comprehensive Laboratory Workup

• If TSB is elevated or rising rapidly, obtain blood type and Coombs' test, complete blood count with peripheral smear, direct or conjugated bilirubin, and reticulocyte count and G6PD level 4, 5, 8
• For elevated direct/conjugated bilirubin, evaluate for urinary tract infection, sepsis, and metabolic causes such as hypothyroidism and galactosemia 4, 5, 6

Treatment Decision Based on TSB Level

• Use age-specific and risk-stratified nomograms to determine if phototherapy is indicated at 240 hours of life 9, 7
• Phototherapy thresholds are lower for infants with risk factors including gestational age 35-37 weeks, hemolytic disease, G6PD deficiency, sepsis, acidosis, or albumin <3.0 g/dL 9, 7

Feeding Management

• Continue frequent breastfeeding if the infant is clinically well and jaundice is mild to moderate, and do not routinely supplement with water or dextrose water in nondehydrated breastfed infants 7
• Assess adequacy of intake by monitoring weight, voiding pattern, and stooling pattern 9, 7

Critical Pitfalls to Avoid

• Visual estimation of bilirubin is unreliable, particularly in infants with darker skin pigmentation, and always obtain objective TSB or TcB measurements when jaundice is suspected 4, 5, 8
• Never subtract direct bilirubin from total bilirubin when making decisions about phototherapy or exchange transfusion, and use the total bilirubin value for treatment decisions 6
• Recognize high-risk populations, including infants with G6PD deficiency and East Asian infants, who have a higher risk of significant hyperbilirubinemia 4, 8, 9

Newborn Bilirubin Management

Risk Stratification and Decision Framework

• A bilirubin level of 7.3 mg/dL at 37 hours in a clinically well newborn falls in the intermediate-risk zone on the American Academy of Pediatrics (AAP) hour-specific nomogram, well below thresholds requiring phototherapy for any risk category 10, 11
• This level is not in the high-risk zone (>95th percentile) that would mandate immediate intervention or close monitoring 11

Risk Factors That Modify Approach

• The AAP recommends assessing for specific risk factors that would lower phototherapy thresholds and necessitate closer follow-up, including isoimmune hemolytic disease (ABO or Rh incompatibility with positive direct Coombs test) 10, 11
• The AAP also recommends assessing for G6PD deficiency, particularly in infants of certain ethnic descent 10
• Exclusive breastfeeding with inadequate intake, excessive weight loss, or signs of dehydration is also a risk factor that requires closer monitoring 10

Follow-Up Timing Based on Discharge Age

• The AAP provides specific follow-up requirements, including that infants discharged before 24 hours must be seen by 72 hours of age, those discharged between 24-48 hours must be seen by 96 hours of age, and those discharged between 48-72 hours must be seen by 120 hours of age 11

Critical Pitfalls to Avoid

• The AAP recommends never relying on visual estimation of jaundice severity, particularly in darkly pigmented infants, and always obtaining objective measurement if there is any doubt 11
• The AAP also recommends not treating 35-37 week infants as term infants, as they require closer monitoring and have lower phototherapy thresholds 10
• Ensuring adequate follow-up is arranged before discharge is crucial, and if appropriate follow-up cannot be ensured in the presence of risk factors, discharge should be delayed until 72-96 hours 11

Specific Recommendations for Your Patient

• For a clinically well newborn with bilirubin 7.3 mg/dL at 37 hours, the AAP recommends documenting the absence of risk factors, providing written and verbal parent education, and scheduling follow-up by 96 hours of age 11
• The AAP also recommends instructing parents to return immediately if jaundice worsens, feeding decreases, or the infant becomes lethargic 11